Apogee Therapeutics to Host Conference Call on July 7, 2025, to Discuss Phase 2 APEX Trial Part A 16-Week Data for APG777 in Moderate-to-Severe Atopic Dermatitis

CNBC Exclusive: Apogee Therapeutics to Unveil Key Data for Novel Inflation Drug

SAN FRANCISCO and BOSTON, July 6, 2025

Apogee Therapeutics, Inc. (Nasdaq: APGE), a biotech firm focused on developing groundbreaking treatments for major inflammatory and immunology (I&I) markets, is set to release significant 16-week data from its Phase 2 APEX trial of its lead candidate, APG777. The data, pertaining to Part A of the trial, will be announced on Monday, July 7, 2025. Following the announcement, Apogee will host a conference call and webcast at 8:00 a.m. ET to delve into the findings.

This highly anticipated data could offer critical insights into APG777’s potential to deliver differentiated efficacy and novel dosing regimens for conditions such as atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), and chronic obstructive pulmonary disease (COPD), among other I&I indications.

Webcast Details
Apogee Therapeutics’ live webcast of the Phase 2 APEX trial’s Part A results will commence on Monday, July 7^th at 8:00 a.m. ET. Investors and interested parties can access the live broadcast via the company’s website in the Investors section at https://investors.apogeetherapeutics.com/news-events/events. A replay of the webcast will be made available post-call.

About Apogee
Apogee Therapeutics is at the forefront of clinical-stage biotechnology, spearheading the development of novel biologics. Their focus is on creating treatments with the potential for superior efficacy and more convenient dosing in the expansive inflammatory and immunology markets. Apogee’s innovative antibody programs are engineered to tackle the limitations of current therapies, targeting validated mechanisms of action with advanced antibody engineering for optimized characteristics, including extended half-life. APG777, their most advanced program, is initially being developed for atopic dermatitis, a significant and underserved market within the I&I landscape. With a robust pipeline and a deep bench of scientific expertise, Apogee is strategically positioned to deliver best-in-class results and significant value to patients who are currently experiencing unmet needs.